Exact Mass: 434.2628
Exact Mass Matches: 434.2628
Found 500 metabolites which its exact mass value is equals to given mass value 434.2628,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Glutathionylspermidine
The spermidine amide of glutathione.
Lexibulin
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
(12S,15S)-15-O-Demethyl-10,29-dideoxy-11,12-dihydro-striatin C
(12S,15S)-15-O-Demethyl-10,29-dideoxy-11,12-dihydro-striatin C is found in mushrooms. (12S,15S)-15-O-Demethyl-10,29-dideoxy-11,12-dihydro-striatin C is a constituent of Hericium erinaceum (lions mane)
LysoPA(0:0/18:2(9Z,12Z))
LysoPA(0:0/18:2(9Z,12Z)) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293).
LysoPA(18:2(9Z,12Z)/0:0)
LPA(18:2(9Z,12Z)/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293) [HMDB] LysoPA(18:2(9Z,12Z)/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293).
Polysorbate 60
Polysorbate 60 is an emulsifier, opacifier, protective coating, dough conditioner, dispersant, wetting agent, stabiliser, defoamer, poultry scald agent, flavour.Polysorbates are a class of emulsifiers used in some pharmaceuticals and food preparation. They are often used in cosmetics to solubilize essential oils into water-based products. Polysorbates are oily liquids derived from PEG-ylated sorbitan (a derivative of sorbitol) esterified with fatty acids. (Wikipedia). Emulsifier, opacifier, protective coating, dough conditioner, dispersant, wetting agent, stabiliser, defoamer, poultry scald agent, flavour.
Butyl oleate sulfate
Surfactant. Butyl oleate sulfate is used in dehydration of grapes to produce raisins and as a coating for citrus fruits. Surfactant. It is used in dehydration of grapes to produce raisins and as a coating for citrus fruits
Erinacine C
Erinacine C is found in mushrooms. Erinacine C is a metabolite of Hericium erinaceum (lions mane).
Urea, N-butyl-N'-(2-(3-(5-ethyl-4-phenyl-1H-imidazol-1-yl)propoxy)-6-methylphenyl)-
Lexibulin
Ribociclib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EF - Cyclin-dependent kinase (cdk) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
MG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/0:0)
MG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/0:0)
MG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0)
MG(0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0)
MG(0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
DG(2:0/20:4(6E,8Z,11Z,14Z)+=O(5)/0:0)
DG(2:0/20:4(6E,8Z,11Z,14Z)+=O(5)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(6E,8Z,11Z,14Z)+=O(5)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0/0:0)
DG(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6E,8Z,11Z,14Z)+=O(5)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(6E,8Z,11Z,14Z)+=O(5))
DG(2:0/0:0/20:4(6E,8Z,11Z,14Z)+=O(5)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,14Z)+=O(5)/0:0/2:0)
DG(20:4(6E,8Z,11Z,14Z)+=O(5)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,13E)+=O(15)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,13E)+=O(15)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,13E)+=O(15)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,13E)+=O(15)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,13E)+=O(15))
DG(2:0/0:0/20:4(5Z,8Z,11Z,13E)+=O(15)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,13E)+=O(15)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,13E)+=O(15)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0)
DG(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0/0:0)
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R))
DG(2:0/0:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0/2:0)
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0)
DG(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0/0:0)
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18))
DG(2:0/0:0/20:5(5Z,8Z,11Z,14Z,16E)-OH(18)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0/2:0)
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0)
DG(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0/0:0)
DG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12))
DG(2:0/0:0/20:5(5Z,8Z,10E,14Z,17Z)-OH(12)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0/2:0)
DG(20:5(5Z,8Z,10E,14Z,17Z)-OH(12)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0)
DG(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0/0:0)
DG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5))
DG(2:0/0:0/20:5(6E,8Z,11Z,14Z,17Z)-OH(5)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0/2:0)
DG(20:5(6E,8Z,11Z,14Z,17Z)-OH(5)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
3beta-Malonyloxy-15-acetoxy-ent-labda-7,13E-dien methylester
methyl 2-(9-(cyclohexylmethyl)-9H-carbazole-3-carboxamido)-3,3-dimethylbutanoate
(all-Z)-5,7-dihydroxy-2-nonadeca-4,7,10,13,16-pentenyl-chromone|5,7-dihydroxy-2-((4Z,7Z,10Z,13Z,16Z)-nonadeca-4,7,10,13,16-pentaen-1-yl)-4H-chromen-4-one|5,7-dihydroxy-2-((4Z,7Z,10Z,13Z,16Z)-nonadeca-4,7,10,13,16-pentaenyl)-4H-chromen-4-one|5,7-dihydroxy-2-(4Z,7Z,10Z,13Z,16Z-nonadecapentaenyl)chromone
1alpha-(beta-D-glucopyranosyloxy)eudesma-3alpha,4beta,11-triol
9,10-diangeloyloxy-11-hydroxy-10,11-dihydrobrickelliol
2-Benzoyl-3,5-dihydroxy-4,4,6-tris(3-methyl-2-butenyl)-2,5-cyclohexadien-1-one
Tri-Ac-(3beta,5alpha,16alpha,17alpha)-Androstane-3,16,17-triol
15-(3-Hydroxy-2-methylbutanoyl)-(ent-15beta)-9, 15-Dihydroxy-16-kauren-19-oic acid
6alpha,8alpha-dihydroxy-23-carboxy-labd-13(14),17-dien-16,19-olide
16-(4,9-dihydro-3H-beta-carbolin-1-yl)-17-nor-coryn-19-ene|3,4-Dihydro-usambarensin
7-oxo-13alpha-methoxy-8,11,13-abietatriene-18-succinic acid|abiesadine U
3,21-Di-Ac-(3alpha,5beta)-3,14,21-Trihydroxypregnan-20-one
3,21-Di-Ac-(3beta,5alpha,17alphaOH)-3,17,21-Trihydroxypregnan-20-one
17-Angeloyl-(ent-12alpha,16alphaOH)-12,16,17-Trihydroxy-19-kauranoic acid|ent-12alpha,16alpha-dihydroxy-17-angeloxykauran-19-oic acid
8alpha,15(S),23alpha-trihydroxy-23,6alpha-epoxy-labd-13(14),17-dien-16(S),19-olide
(1RS,5RS,7RS)-3-benzoyl-4-hydroxy-8,8-dimethyl-1,7-bis(3-methylbut-2-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione|garciniaphenone
(10R,6E)-7,11-dimethyl-3-methylene-6-dodecaene-1,2,10,11-tetraol 10-O-beta-D-glucopyranoside|trikamsesquiside A
2-hydroxy-3-[(1-oxododecyl)oxy]propyl-beta-D-glucopyranoside
ent-19-(Z)-coumaroyloxylabda-8(17),13(16),14-triene
Na, Nb-Didemethylisoalfileramine|Na,Nb-Di-de-Me-Isoalfileramine
abiesadine V|methyl 7-oxo-13beta-hydroxy-8,11,13-abietatriene-18-succinate
Tri-Ac-(3beta,5alpha,6alpha,17alpha)-Androstane-3,6,17-triol
longipinane-7beta,8alpha,9alpha-triol-1-one 7-angelate-8-methylbutyrate
6alpha,8alpha,15(S)-trihydroxy-23-oxo-labd-13(14),17-dien-16(S),19-olide
9beta-acetoxy-11beta,12beta-epoxy-13alpha-hydroxy-3alpha-propionoxy-1beta,8beta-trinervit-15(17)-ene
2alpha-Angeloyloxy-3beta-(2-methylbutanoyloxy)isodrimeninol
(ent-15beta)-2,3-Dihydroxy-2-methylbutanoyl-15-Hydroxy-16-kauren-19-oic acid|2,3-Dihydroxy-2-methylbutanoyl-15-Hydroxy-16-kauren-19-oic acid
8-Angeloyl,9-(3-mehtylbutanoyl)-(3beta,8alpha,9beta,10b)-8,9,10-Trihydroxy-5-longipinanone
11-hydroxy-8,11,13-abietatriene 12-O-beta-D-xylopyranoside
13-oxo-7-[3,4,5-trihydroxy-6-(methoxymethyl)oxan-2-yl]oxytetradecanoic acid
[(2R)-2-[(E,2S,4R)-4,6-dimethyloct-6-en-2-yl]-6-oxo-2,3-dihydropyran-3-yl] (2E,4E,6S)-8-hydroxy-6-(hydroxymethyl)-4-methylocta-2,4-dienoate
Bis[2-(2-butoxyethoxy)ethyl] adipate
CONFIDENCE standard compound; INTERNAL_ID 1254; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9768; ORIGINAL_PRECURSOR_SCAN_NO 9763 CONFIDENCE standard compound; INTERNAL_ID 1254; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9764; ORIGINAL_PRECURSOR_SCAN_NO 9760 CONFIDENCE standard compound; INTERNAL_ID 1254; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9787; ORIGINAL_PRECURSOR_SCAN_NO 9784 CONFIDENCE standard compound; INTERNAL_ID 1254; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9800; ORIGINAL_PRECURSOR_SCAN_NO 9798 CONFIDENCE standard compound; INTERNAL_ID 1254; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9802; ORIGINAL_PRECURSOR_SCAN_NO 9800 CONFIDENCE standard compound; INTERNAL_ID 1254; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9812; ORIGINAL_PRECURSOR_SCAN_NO 9809
Ala Phe Val Val
Ala Val Phe Val
Ala Val Val Phe
Cys Gly Lys Lys
Cys Lys Gly Lys
Cys Lys Lys Gly
Phe Ala Val Val
Phe Gly Ile Val
Phe Gly Leu Val
Phe Gly Val Ile
Phe Gly Val Leu
Phe Ile Gly Val
Phe Ile Val Gly
Phe Leu Gly Val
Phe Leu Val Gly
Phe Val Ala Val
Phe Val Gly Ile
Phe Val Gly Leu
Phe Val Ile Gly
Phe Val Leu Gly
Phe Val Val Ala
Gly Cys Lys Lys
Gly Phe Ile Val
Gly Phe Leu Val
Gly Phe Val Ile
Gly Phe Val Leu
Gly Ile Phe Val
Gly Ile Val Phe
Gly Lys Cys Lys
Gly Lys Lys Cys
Gly Leu Phe Val
Gly Leu Val Phe
Gly Val Phe Ile
Gly Val Phe Leu
Gly Val Ile Phe
Gly Val Leu Phe
Ile Phe Gly Val
Ile Phe Val Gly
Ile Gly Phe Val
Ile Gly Val Phe
Ile Thr Thr Thr
Ile Val Phe Gly
Ile Val Gly Phe
Lys Cys Gly Lys
Lys Cys Lys Gly
Lys Gly Cys Lys
Lys Gly Lys Cys
Lys Lys Cys Gly
Lys Lys Gly Cys
Leu Phe Gly Val
Leu Phe Val Gly
Leu Gly Phe Val
Leu Gly Val Phe
Leu Thr Thr Thr
Leu Val Phe Gly
Leu Val Gly Phe
Thr Ile Thr Thr
Thr Leu Thr Thr
Thr Thr Ile Thr
Thr Thr Leu Thr
Thr Thr Thr Ile
Thr Thr Thr Leu
Val Ala Phe Val
Val Ala Val Phe
Val Phe Ala Val
Val Phe Gly Ile
Val Phe Gly Leu
Val Phe Ile Gly
Val Phe Leu Gly
Val Phe Val Ala
Val Gly Phe Ile
Val Gly Phe Leu
Val Gly Ile Phe
Val Gly Leu Phe
Val Ile Phe Gly
Val Ile Gly Phe
Val Leu Phe Gly
Val Leu Gly Phe
Val Val Ala Phe
Val Val Phe Ala
1a,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide / 1a,25-dihydroxy-3-deoxy-3-thiacholecalciferol 3-oxide
(5Z,7E)-(1R,3R)-1,25-dihydroxy-9,10-seco-3-thia-5,7,10(19)-cholestatriene3-oxide
(5Z,7E)-(1R,3S)-1,25-dihydroxy-9,10-seco-3-thia-5,7,10(19)-cholestatrien 3-oxide
1α,25-dihydroxy-22-thiavitamin D3 / 1α,25-dihydroxy-22-thiacholecalciferol
1α,25-dihydroxy-22-thia-20-epivitamin D3 / 1α,25-dihydroxy-22-thia-20-epicholecalciferol
1α,25-dihydroxy-23-thiavitamin D3 / 1α,25-dihydroxy-23-thiacholecalciferol
(5Z,7E)-(1S,3R)-24-(dimethylphosphoryl)-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide / 1alpha,25-dihydroxy-3-deoxy-3-thiacholecalciferol 3-oxide
(5E,7E)-(1R,3S)-1,25-dihydroxy-9,10-seco-3-thia-5,7,10(19)-cholestatriene 3-oxide
1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide
(5E)-(3S)-1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide
(5Z)-1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide
(5Z)-(3S)-1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide
1alpha,25-dihydroxy-22-thiavitamin D3
1alpha,25-dihydroxy-22-thia-20-epivitamin D3
1alpha,25-dihydroxy-23-thiavitamin D3
1alpha-hydroxy-24-(dimethylphosphoryl)-25,26,27-trinorvitamin D3
(R)-1-BOC-4-(3-CBZ-AMINO-3-METHOXYCARBONYL-PROPYL)PIPERIDINE
4-(TERT-BUTYLDIMETHYLSILANYLOXY)-6-[2-(8-HYDROXY-2,6-DIMETHYL-1,2,6,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL)ETHYL]TETRAHYDROPYRAN-2-ONE
1-N,4-N-bis(2-methylphenyl)-3,6-dipropyl-1,2,4,5-tetrazine-1,4-dicarboxamide
methyl 2-[[(2E)-2-benzylideneoctylidene]amino]benzoate
5-CHLORO-4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1-(TRIISOPROPYLSILYL)-1H-PYRROLO[2,3-B]PYRIDINE
(S)-1-CYCLOHEXYL-4-(4-(2-METHOXYPHENYL)PIPERAZIN-1-YL)-2-METHYL-2-PHENYLBUTAN-1-ONE
2-(4-piperazin-1-ylanilino)-N-(4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl)pyrimidine-4-carboxamide
sodium 2-[2-[2-(tridecyloxy)ethoxy]ethoxy]ethyl sulphate
2-[2-(2,3-dihydro-5-methoxy-2,3,3-trimethyl-1H-indol-1-yl)vinyl]-1,3,3-trimethyl-3H-indolium acetate
4-CHLORO-5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1-(TRIISOPROPYLSILYL)-1H-PYRROLO[2,3-B]PYRIDINE
N-[2-(2-aminoethylamino)ethyl]ethane-1,2-diamine,formaldehyde,2-[(2-methylphenoxy)methyl]oxirane,phenol
1-N,4-N-bis(3-methylphenyl)-3,6-dipropyl-1,2,4,5-tetrazine-1,4-dicarboxamide
(2-(7-(2-(4-Cyano-2-fluorophenoxy)ethyl)-9-oxa-3,7-diazabicyclo(3.3.1)non-3-yl)ethyl)carbamic acid tert-butyl ester
Oxogestone phenpropionate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone
(1R,3S,5E)-5-[(2E)-2-[(3aS,7aR)-1-[1-(2-hydroxy-2-methylpropyl)sulfanylpropan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
D018977 - Micronutrients > D014815 - Vitamins > D004100 - Dihydroxycholecalciferols D018977 - Micronutrients > D014815 - Vitamins > D006887 - Hydroxycholecalciferols
Ribociclib
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EF - Cyclin-dependent kinase (cdk) inhibitors C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
(5Z)-1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide/(5Z)-1alpha,25-dihydroxy-3-deoxy-3-thiacholecalciferol 3-oxide
(2R)-2-acetamido-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl]sulfanylpropanoate
(2S)-2-amino-5-[[(2R)-1-[[2-[4-(3-aminopropylamino)butylamino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid
13-(Hydroxymethyl)-2,5-dimethyl-8-propan-2-yl-15,20,22-trioxapentacyclo[12.8.0.02,10.05,9.016,21]docosa-8,12-diene-17,18-diol
MG(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0/0:0)
MG(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0/0:0)
MG(0:0/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/0:0)
MG(0:0/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/0:0)
[3,9-Dicarboxy-2,10-dihydroxy-5-methyl-4,8-dioxo-11-(trimethylazaniumyl)undecyl]-trimethylazanium
N-[2-(tert-butylamino)-2-oxo-1-(3-pyridinyl)ethyl]-N-(4-tert-butylphenyl)-5-oxazolecarboxamide
N-[2-(cyclopentylamino)-2-oxoethyl]-4,7-dimethyl-N-(2-methylphenyl)-2-oxo-3H-pyrido[1,2-a]pyrimidine-4-carboxamide
(2E,4E,8S,10E,12Z)-1-[(3E,5S)-5-[(4-hydroxyphenyl)methyl]-2,4-dioxopyrrolidin-3-ylidene]-4,8-dimethyltetradeca-2,4,10,12-tetraen-1-olate
1-[[(2R,3R)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
(8R,9S,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8R,9R,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(6S,7S,8S)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8R)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
1-[(1R)-1-(hydroxymethyl)-7-methoxy-2-(3-pyridinylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone
[(1R)-1-(hydroxymethyl)-7-methoxy-2,9-dimethyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-(3-pyridinyl)methanone
cyclohexyl-[(2S,3R)-2-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone
cyclohexyl-[(2R,3R)-2-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone
1-[[(2S,3S)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2S,3S)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2R,3R)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2S,3R)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2R,3S)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2R,3S)-9-(dimethylamino)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[[(2S,3R)-9-(dimethylamino)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
1-[(4R,7R,8S)-5-ethyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
(8S,9S,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8R,9S,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8R,9R,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9R,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9R,10S)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
(8S,9S,10R)-N-cyclopentyl-10-(hydroxymethyl)-9-[4-(3-pyridinyl)phenyl]-1,6-diazabicyclo[6.2.0]decane-6-carboxamide
1-[(1R)-1-(hydroxymethyl)-7-methoxy-2-(2-pyridinylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]ethanone
(6S,7S,8R)-N-cyclohexyl-8-(hydroxymethyl)-2-oxo-7-(4-pyridin-4-ylphenyl)-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
1-[(1S)-1-(hydroxymethyl)-7-methoxy-2-(3-pyridinylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone
cyclohexyl-[(2S,3S)-2-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone
cyclohexyl-[(2R,3S)-2-(hydroxymethyl)-1-[(3-methoxyphenyl)methyl]-3-phenyl-1,6-diazaspiro[3.3]heptan-6-yl]methanone
[(1S)-1-(hydroxymethyl)-7-methoxy-2,9-dimethyl-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]yl]-(3-pyridinyl)methanone
[(4E,8E)-2-acetamido-3-hydroxytrideca-4,8-dienyl] 2-(trimethylazaniumyl)ethyl phosphate
[(4E,8E)-3-hydroxy-2-(propanoylamino)dodeca-4,8-dienyl] 2-(trimethylazaniumyl)ethyl phosphate
13-Oxo-7-[3,4,5-trihydroxy-6-(methoxymethyl)oxan-2-yl]oxytetradecanoic acid
1-Oleoylglycerone 3-phosphate
A 1-acylglycerone 3-phosphate in which the acyl group is specified as oleoyl.
(2R)-2-[(2R,3R,4S)-3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-hydroxyethyl dodecanoate
(12S,15S)-15-O-Demethyl-10,29-dideoxy-11,12-dihydro-striatin C
lysophosphatidic acid 0:0/18:2(9Z,12Z)
A 2-acyl-sn-glycerol 3-phosphate having (9Z,12Z)-octadeca-9,12-dienoyl as the 2-O-acyl group.
1-linoleoyl-sn-glycerol 3-phosphate
A 1-acyl-sn-glycerol 3-phosphate having linoleyl (9Z,12Z-octadecadienoyl) as the 1-O-acyl group.
1-Oleoyl-sn-glycero-3-phosphate(2-)
A 1-acyl-sn-glycerol 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-oleoyl-sn-glycero-3-phosphate.
1-stearoylglycerone 3-phosphate(2-)
A 1-acylglycerone 3-phosphate(2-) obtained by deprotonation of the phospho groups of 1-stearoylglycerone 3-phosphate; major species at pH 7.3.
2-Oleoyl-sn-glycero-3-phosphate(2-)
A 2-acyl-sn-glycero-3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 2-oleoyl-sn-glycero-3-phosphate; major species at pH 7.3.
